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Abstract 
Purpose: To identify effective molecular diagnostic methods for oral squamous cell carcinoma (OSCC) 
to facilitate treatment of the disease in its initial stages. 
Methods: To identify molecular markers, OSCC tissue samples were collected from cancer patients 
and healthy controls. CD44+ cells were sorted using quantitative real-time polymerase chain reaction 
(qRT-PCR). Immunohistochemistry and immunostaining experiments were performed to identify 
markers for OSCC. 
Results: The qRT-PCR data confirmed the presence of oncogenic miR-155 in the OSCC samples. The 
immunohistochemical and immunostaining results confirmed the expression of Oct-4, an important 
target for the early diagnosis of OSCC, in oncogenic miR-155-positive OSCCs. 
Conclusion: Detection of the expression of miR-155 and Oct-4, which are key molecular markers, may 
be useful in improving the early diagnosis of OSCC. 
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Oral squamous cell carcinoma (OSCC) is the 
sixth most prevalent cancer in the world and the 
third most common cancer in developing 
countries [1,2]. Further, OSCC is the sixth most 
common cancer in males and the tenth most 
common cancer in females [3]. The prognosis of 
the disease is poor [4]. Therefore, it is important 
to identify relevant signaling pathways, including 
molecular markers, for improved diagnosis of the 
disease [5]. Recently, it was reported that OSCC 
is functionally heterogeneous [6,7], making it 
more complex to identify molecular markers that 
will lead to improved diagnosis. Novel in-depth 
analysis is essential to diagnose OSCC in the 
early stages, which is key to overcoming the 
disease. One study investigated non-coding 
RNAs, which have a vital regulatory role in most 
cancers. In particular, microRNAs (miRNAs) 
have many regulatory roles, including a major 
role in the post-transcriptional regulation of 
various genes [8]. In addition, it has been 
reported that miRNAs are important in the 
regulation of various cancers [9]. The 
transcription factor Oct-4, a member of the POU 
domain family, is present in pluripotent 
embryonic stem and germ cells [10-12].  
 
The present study demonstrates the expression 
of Oct-4 in oncogenic miRNA (miR-155)-positive 
cells. Detection of the expression of miR-155 and 
Oct-4, which are key molecular markers for 
OSCC, may improve diagnosis and facilitate 
early identification of the disease.  
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In total, 22 OSCC and 22 normal oral tissue 
samples were collected from patients and 
healthy volunteers. The tumor samples were 
collected mostly from the cheek and tongue 
using a recognized procedure. Immediately after 
collection, the tumor specimen samples were 
snap-frozen using liquid nitrogen and stored at – 
80 ºC until RNA extraction. All biopsy tumor 
specimens were confirmed to contain > 90 % 
tumor cells. International guidelines were 
followed in the study in accordance with the rules 
set in the Declaration of Helsinki, Finland [13]. 
Written informed consent was obtained from the 
patients and in addition approval was also 
received from the ethical committee of the 
institute (Department of Oral and Maxillofacial 
Surgery, Army Hospital, Huzhou, Zhejiang-
313000, PR China with Ref.No.OMS/22/2016) 
prior to the start of the study. The institutional 
Biological Safety Committee monitored the 




The samples collected from the OSCC patients 
and controls were labeled with PE mouse anti-
human CD44 antibodies (BD Biosciences 
Pharmingen, San Diego, CA) and detected using 
a FACSCalibur flow cytometer (Becton Dickinson 
Immunocytometry Systems, San Jose, CA). 
Appropriate irrelevant antibodies (isotypes) were 





Total RNA was extracted from the two groups of 
samples using TRIzol reagent (Invitrogen Corp., 
Carlsbad, CA) as per the manufacturer’s 
instructions. The OSCC samples were 
homogenized in TRIzol reagent using 1 mL per 
50 to 100 mg of tissue. The concentration and 
quality of the RNA were determined using a 
NanoDrop spectrophotometer (Wilmington, DE), 
and the RNA integrity was assessed by agarose 
gel electrophoresis (Bio-Rad, Hercules, CA). The 
isolated total RNA was stored at – 80 ºC for 
further analysis. 
 
Quantification of miR-34a by quantitative real-
time polymerase chain reaction (qRT-PCR) 
 
The miR-155 level was analyzed using a 
TaqMan MicroRNA Assay. Total RNA was 
isolated from the CD44+ sorted cells followed by 
the recovery of small RNA fractions (< 200 
nucleotides) using a mirVANA PARIS miRNA 
Isolation Kit (Ambion Inc., Foster City, CA). The 
integrity of the RNA was checked using a 
NanoDrop spectrophotometer at an absorbance 
of 260 nm. qRT-PCR was performed using a 
threshold cycle (Ct) as the fractional cycle 
number at which the fluorescence exceeds the 
fixed threshold of 0.2. Quantitative miR-34a 
expression was analyzed using dCt (the Ct value 
normalized to internal ‘housekeeping’ miRNAs 
such as miR-24 and miR-103) and ddCt (the 
difference between the dCt of the positive 
population and that of the negative population) 
values for each of the miRNAs. The percentage 
of expression was calculated using the formula ‘2 





OSCC tissue samples were collected from 
cancer patients and subjected to 
immunohistochemistry. The samples were 
formalin-fixed and paraffin-embedded using 
standard protocols. The tissue sections (7 µm) 
were deparaffinized and hydrated. Antigens were 
retrieved by Tri-sodium citrate treatment (pH 
6.0). Endogenous peroxides and nonspecific 
immune staining were blocked by hydrogen 
peroxide and normal serum, respectively. The 
sections were then incubated overnight at 4 ºC 
with a monoclonal anti-CD44+ antibody. After 
incubation with the primary antibody, the tissue 
sections were washed and incubated with 
horseradish peroxidase-conjugated secondary 
antibodies. The washed slides were developed 
with 3,3'-diaminobenzidine (DAB). The prepared 
slides were counterstained, mounted with DPX, 




The CD44+ sorted OSCC samples were fixed 
with 4 % paraformaldehyde, permeabilized with 
Triton X-100, and blocked with 1 % bovine serum 
albumin in phosphate-buffered saline (PBS) for 1 
h. The cells were incubated with anti-Oct-4 
antibodies (Sigma-Aldrich, St. Louis, MO) 
overnight at 4 °C. The plates were washed in 1 × 
PBS and incubated with secondary 
fluorochrome-conjugated antibodies for 45 min in 
the dark and observed using a Nikon Ti-S 




Statistical analysis, including mean, standard 
deviation, standard error and ANOVA for qRT-
PCR data, were performed using Microsoft Office 
Excel 2007 (Microsoft Corp., Redmond, WA). 
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Histological features of OSCC tissue samples 
 
Molecular markers for the diagnosis of OSCC in 
the initial stages of the disease are not well 
established. Identification of the molecular 
pathways related to OSCC will aid in the design 
of novel molecular markers for the early and 
effective detection of OSCC in the initial stages. 
The present project was designed with this in 
mind. OSCC tissue samples were collected from 
the patients as described in the Experimental 
section using standard procedures and stored 
accordingly. The OSCC samples were screened 
using histological techniques. The samples were 
carefully observed using histological analysis by 
a pathologist and specialized scientist. All biopsy 
tumor specimens were observed and confirmed 
by histological analysis to contain > 90 % tumor 
cells. The confirmed 22 OSCC samples were 
further processed for various analyses. 
 
Flow cytometry results 
 
To isolate OSCC cells from the surrounding 
tissues, flow cytometry was performed. Normal 
and OSCC tissue samples were harvested and 
placed in Dulbecco’s modified Eagle’s medium. 
The procedure for cell isolation was performed 
as described previously with slight modifications. 
In short, after digestion with collagenase at 37 °C 
for 15 min, tissues were squashed and the cell 
suspension was passed through a 40 µm nylon 
mesh. The processed cells were analyzed by 
flow cytometric sorting for CD44+ cells. The 
results are shown in Fig. 1. The sorted cells from 
the normal and OSCC tissue samples are shown 




To study the expression pattern of miR-155, total 
RNA was isolated from the CD44+ sorted cells of 
normal and OSCC tissue samples using TRIzol 
reagent. The integrity of the RNA was checked 
with a NanoDrop spectrophotometer. For qRT-
PCR, 10 ng of RNA were used. The qRT-PCR 
data are shown in Fig 2. The data show the 
expression profile of miR-155 in normal and 
OSCC tissue samples. The experiments were 
repeated thrice with the same samples; the same 
results were obtained as shown in Fig 2. The 
relative expression of miR-155 was reduced in 
normal cells, whereas the level was increased in 




To identify whether OSCC samples (CD44+ cells) 
express Oct-4, immunohistochemistry was 
performed. The OSCC tissue and control 
samples were fixed with 10 % neutral buffered 
formalin, processed for immunohistochemistry, 
and stained with anti-Oct-4 and anti-CD44+ 
antibodies. The data are shown in Fig 3A to D. 
Figure 3B shows CD44+ cells in the OSCC 
samples, whereas Fig. 3D shows no expression 
of CD44 in the control samples. Figure 3A shows 
Oct-4-positive cells in the OSCC samples, 
whereas Fi. 3C shows no Oct-4-positive cells in 




To confirm and validate that the OSCC samples 
sorted with CD44+ cells were Oct-4-positive, 
immunostaining was performed using anti-Oct-4 
antibodies. Oct-4 is a transcription factor and 
well-known stem cell marker. The CD44+ cells 
were immunostained with anti-Oct-4 antibodies 
and the plates were examined using a Nikon Ti-S 
fluorescence microscope; Oct-4-positive cells 
were observed (Fig 4A). This finding confirms 




Figure 1: Flow cytometry data. OSCC and normal tissue samples were subjected to cell sorting for CD44+ cells. 
A. In the normal samples, 0 % of the cells were CD44+. B. In the OSCC samples, 1.85 % of the cells were CD44+ 
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Figure 2: qRT-PCR analysis of the expression of oncogenic miR-155. RNA was isolated from the CD44+ sorted 
cells of OSCC and normal tissue samples and subjected to qRT-PCR. The OSCC cells showed miR-155 
expression in all samples when compared with the controls 
 
 
Figure 3: Immunohistochemistry. A. CD44+ cells in the OSCC samples appear brown. B. The OSCC samples 
contained Oct-4-positive cells (indicated by an arrow). C. Normal oral tissue samples showed no CD44 
expression. D. Normal oral samples showed no Oct-4 expression. CD44- and Oct-4-positive cells were stained 




As stated earlier, OSCC is the sixth most 
frequent cancer in the world; thus, an effective 
early diagnostic method is needed to overcome 
the severity of the disease and provide effective 
treatment. In the present study, the molecular 
link between OSCC and Oct-4 was documented 
and validated. In total, 22 tumor specimen 
samples were analyzed histologically and 
confirmed to contain > 90 % tumor cells. The 22 
tissue samples used in this study were positive 
for OSCC. 
 
The present experiment was designed to identify 
the molecular link between Oct-4 and miR-155 in 
OSCC. The OSCC positive samples were 
subjected to flow cytometry to sort CD44+ cells. It 
has been reported that CD44 and CD133 are 
cancer stem cell markers [14-16]. The data (Fig. 
1) show the flow cytometric analysis of CD44 in 
both normal and OSCC tissue samples. 
Interestingly, CD44+ cells were seen in the 
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OSCC tissue samples but not in the control 
samples. These data illustrate and confirm that 
the OSCC tissue samples were tumor cells. 
 
 
Figure 4: Immunostaining analysis. Immunostaining of 
the CD44+ OSCC samples with anti-Oct-4 antibodies 
produced a fluorescent signal 
 
To identify the expression of oncogenic miR-155 
in the CD44+ sorted OSCC samples, qRT-PCR 
was performed. The data obtained illustrate that 
the expression of miR-155 was increased 
compared with that in the normal samples. The 
data confirm that oncogenic miR-155 was highly 
expressed in OSCC patients compared to the 
controls. 
 
The expression of Oct-4 in CD44+ OSCC cells 
was confirmed by immunohistochemistry. The 
results clearly show that Oct-4 was expressed in 
the nucleus. The data also suggest that CD44 is 
a membrane receptor protein, as the signal was 
obtained from the border of the cells. Based on 
the data, it is suggested that OSCC samples 
express Oct-4. In addition, in accordance with 
the qRT-PCR and immunohistochemistry data, it 
was confirmed that oncogenic miR-155 was 
expressed in the OSCC samples. 
 
To further validate the data, whether the CD44+ 
cells expressed Oct-4 was determined by 
immunostaining. CD44+ sorted cells from the 
OSCC samples were used for the 
immunostaining experiments and stained with 
anti-Oct-4 antibodies. The results show that the 
CD44+ OSCC samples expressed Oct-4. Based 
on these data, it was confirmed and validated 
that Oct-4 was expressed in oncogenic miR-155 
of OSCC samples. Taken together, the present 





This study paves the way for the development of 
a new approach for the early diagnosis of OSCC. 
Detection of the key molecular markers, miR-155 
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